Aleglitazar

**Cat. No.:** HY-14728  
**CAS No.:** 475479-34-6  
**Molecular Formula:** C₂₄H₂₃NO₅S  
**Molecular Weight:** 437.51  
**Target:** PPAR  
**Pathway:** Cell Cycle/DNA Damage  
**Storage:**  
- Powder  
  -20°C  3 years  
  4°C  2 years  
- In solvent  
  -80°C  6 months  
  -20°C  1 month  

**Solvent & Solubility**

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Mass</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.2857 mL</td>
<td>11.4283 mL</td>
<td>22.8566 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4571 mL</td>
<td>2.2857 mL</td>
<td>4.5713 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2286 mL</td>
<td>1.1428 mL</td>
<td>2.2857 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**BIOLOGICAL ACTIVITY**

**Description**
Aleglitazar (R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM. IC50 Value: 2.8 nM (PPAR-α); 4.6 nM (PPAR-γ). Target: PPARα/γ. Aleglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; it is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones.

**IC₅₀ & Target**

<table>
<thead>
<tr>
<th>Target</th>
<th>IC₅₀</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPARγ, IC₅₀</td>
<td>19 nM</td>
</tr>
<tr>
<td>PPARα, IC₅₀</td>
<td>38 nM</td>
</tr>
</tbody>
</table>

**REFERENCES**


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA